Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary

Prelude Therapeutics Incorporated

12/08/2026 14:31

Prelude Therapeutics Incorporated PRLD.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -41 cents.  The mean expectation of three analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -22 cents to -17 cents per share.
Revenue was $5.70 million​; analysts expected zero. 
Prelude Therapeutics Incorporated's reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $13.92 million.
Prelude Therapeutics Incorporated shares had fallen by 0.2% this quarter and gained 83.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.3% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Prelude Therapeutics Incorporated is $8.00, about 33.5% above its last closing price of $5.32
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.20
-0.14
Beat
Mar. 31 2026 
-0.25
-0.13
Beat
Dec. 31 2025 
-0.03
-0.20
Missed
Sep. 30 2025 
-0.37
-0.26
Beat